Delaney William E IV 4

What Happened
William E. Delaney IV, Chief Scientific Officer of Assembly Biosciences, was granted 14,000 restricted stock units (RSUs) on March 29, 2026. The grant is recorded at $0.00 per share (an award, not a purchase) and represents 35% of his annual equity grant. The RSUs were contingent on a Plan amendment and became issuable upon stockholder approval of that amendment on June 4, 2026.

Key Details

• Transaction date: March 29, 2026 (grant); Form 4 filed June 5, 2026.
• Transaction type/code: Award/Grant (A). Shares granted: 14,000 RSUs; reported acquisition price: $0.00.
• Vesting: Four approximately equal installments on March 29 of 2027, 2028, 2029 and 2030, subject to continuous service (per footnote F1).
• Contingency: RSUs were contingent on stockholder approval of an amendment to the 2018 Stock Incentive Plan; became issuable June 4, 2026 (per footnote F1).
• Additional note (F2): Filing references 688 shares acquired under the company’s ESPP on May 14, 2026.
• Shares owned after transaction: Not specified in the provided excerpt of the filing.
• Timeliness: Form 4 was filed on June 5, 2026 for a March 29 grant — this is later than the typical two-business-day reporting window (a late filing).

Context
RSUs are compensation awards that convert to shares as they vest; they do not involve an out-of-pocket purchase by the insider and are not an immediate market buy or sell signal. Vesting over four years ties the award to continued service and is common in executive compensation. The late filing was corrected by the June 5 Form 4, but late reports can be relevant for investors tracking timely insider activity.